Press Release
14 February 2020

4basebio AG announces results of the public share buyback offer
and final purchase price for the share buy back

Heidelberg, Germany, and Cambridge, UK, 14 February 2020 - 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) today publishes the results of the announced share buyback program. The share buyback offer was oversubscribed and the Company will now proceed to acquire the maximum amount of shares tendered in the framework of the public offer, in total up to 5,230,726 shares, for a final purchase price of EUR 1.85 per share. The exact number of shares that will be acquired will be announced once the allocation quota has been determined. The settlement of the offer is expected to take place on 24 February 2020.

David Roth, Chief Financial Officer of 4basebio AG, comments: "4basebio can now successfully acquire the desired number of shares in full. We are pleased with the success of this offer to our shareholders. The program also supports our wider corporate goals as we now look towards the implementation of our proven buy & build strategy."

The share buyback program was announced by a corporate press release on 21 January 2020 as well as on 24 January 2020 on the website of 4basebio AG at and in the Federal Gazette (Bundesanzeiger). In accordance with the offer as of 24 January 2020 and the volume increase decided by the Management Board on 10 February 2020, the offer of 4basebio AG related to a buyback of up to 5,230,726 shares in total in a purchase price range of EUR 1.60 to EUR 1.85. The final purchase price has been determined by the Company pursuant to Section 2.2 b) i) of the offer document at the end of the period. The allocation quota is currently being determined and will be announced separately without delay.

About 4basebio AG:

4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on January 1 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company will focus on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

4basebio AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).

 

For further information, please contact:

4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: 4
Email:
Investors' information:

MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone:
Email:

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###